FIGURE 1. The gap between prevalence and diagnosis of dementia in England.

FIGURE 1The gap between prevalence and diagnosis of dementia in England

Source: Knapp et al.8 Dementia UK report to the Alzheimer's Society, King's College London and London School of Economics and Political Science (estimated actual average prevalence) and General Practice Research Database report to the NAO (reported prevalence based on diagnoses). The graph shows reported prevalence of dementia, based on levels of diagnosis within PCTs, for ages 65 years and upwards in 2006. The estimated actual average prevalence has been calculated using data from the 2007 Dementia UK report8 in conjunction with population estimates from the ONS. The latter does not take into consideration those aged 85 years and above, owing to restrictions on the data available, and as such forms a very prudent estimate of dementia in the >65-year population.

From: 1, Background

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.